LYMPHOMA 101Armaan Khalid

WHAT IS LYMPHOMA?

Cancer of the lymph nodes Lymphoma > Leukaemia Commonly manifest by the development of

lymphadenopathy at single/multiple sites Classified on basis of histological appearance

Hodgkin’s lymphoma (HL) Non-Hodgkin’s lymphoma (NHL)

HODGKIN’S LYMPHOMA (HL)

Involves primarily the lymph nodes ♂:♀ is 1.3:1 Peak incidence is in 3rd decade Tumour of B Cell origin Presence of Reed-Sternberg Cells on

pathology Often presents @ a single site & spreads in a

predictable fashion

AETIOLOGY OF HL

?Link with EBV Evidence linking previous infectious

mononucleosis with HL 40% of patients ↑ EBV titres @ time of

diagnosis

IT’S ALL ABOUT THE REED-STERNBERG’S

Hallmark of HL is Reed-Sternberg cells Large cell w enlarged multilobulated nucleus,

prominent nucleoli & abundant eosinophilic cytoplasm

RS cell variants exist in HL subtypes Staging based on the Ann Arbor Classification

Used to stage both HL & NHL

CLASSIFICATION OF HL

Nodular Sclerosing HL (70%) Typically seen in young adults/adolescents &

involving Mediastinal & neck LN Characteristic cell is the lacunar type RS cells Overall prognosis is good

Mixed Cellularity HL (25%) Most common HL in pt > 50y/o, ♂ predominance Classical RS cells abundant Assoc with B symptoms Commonly affects abdominal LN & spleen Most common HL subtype in HIV +ve population

‘CLASSIC’ REED-STERNBERG CELLS

*Common in mixed-cellular subtype HL

‘LACUNAR-TYPE’ RS CELLS

*Common in nodular sclerosis subtype HL

CLASSIFICATION OF HL

Lymphocyte-rich HL (5%) Characterised by an inflitrate of many small

lymphocytes & RS cells; often an indolent disease

Lymphocyte-depleted HL (1%) Rare & lacks cellular infiltrate with numerous RS

cells Seen in HL assoc with HIV Patients usually w advanced stage disease

Nodular Lymphocyte-predominant HL (5%) Characterised by large number of small resting

lymphocytes admixed with benign histiocytes Classical RS cells difficult to find

Lympho-histiocytic (L&H) variant RS cell (popcorn cell)

PATHOGENESIS OF HL

??? Central issue: Lymphocytes of the B-cell

lineage not expressing immunoglobulins escape apoptosis

?Role of EBV Interferes w normal immune regulatory

mechanisms Often localised to single site & spreads in

pedictable fashion

CLINICAL FEATURES

LN enlargement, esp. Cervical LN Painless & of rubbery consistency Supra-diaphragmatic LNs affected in 80%

Hepatosplenomegaly B symptoms (40%)

Fever, drenching night sweats, weight loss > 10% in 6/12

Pruritis, fatigue, anorexia, lethargy, malaise Sg/Sx due to organ involvement

Due to mass effect (Bone, Lung, Cardiac, Gut) SVC Syndrome

Due to biochemical derangement

BEFORE & AFTER

WHAT IS CAUSING THE BLOCKAGE?

SUPERIOR VENA CAVA SYNDROME

Obstruction of the SVC by an upper mediastinal mass

Sg/Sx Difficulty breathing/swallowing Stridor, swollen, oedematous facies Venous congestion

Ix Imaging (CXR, CT chest, Invasive contrast

venogram) Rx

Based on what is causing the obstruction Steroids, diuretics, stenting, chemo/radioRx

DIFFERENTIALS

Infectious Mononucleosis Lung Ca (Small Cell) HL NHL Rheumatoid Arthritis Sarcoidosis SLE

INVESTIGATIONS

FBE ESR LFT Serum LDH (Correlates with ‘bulk’ of disease) CXR HIV screening CT scan PET scan Bone marrow aspirate & trephine (BMAT) LN biopsy

ANN ARBOR STAGING CLASSIFICATION

Ann Arbor Staging System

Stage I Involvement of 1 LN region or single extra-lymphatic site

Stage II Involvement of >1 LN region on the same side of the diaphragm

Stage III Involvement of LN regions on both sides of the diaphragm

Stage IV Diffuse/disseminated involvement of >1 extranodal organs/tissue

FURTHER DESIGNATIONS TO ANN ARBOR

Further Applicable Designation to the Ann Arbor

A No symptoms

B B symptoms (Fever, night sweats, weight loss)

X Bulky disease (Widening of mediastinum > 1/3)

E Involvement of single extranodal site that is contiguous/proximal to known nodal site

MANAGEMENT

Rx taken with curative intent Rx based on:

Anatomical distribution of disease ‘Bulk’ Presence/Absence of ‘B’ symptoms

EARLY STAGE (IA, IIA, NO BULK)

Brief chemotherapy + radiotherapy Example: ABVD or BEACOPP

A = Adriamycin (Doxorubicin) B = Bleomycin V = Vinblastine D = Dacarbazine

ADVANCED DISEASE

Cyclical combination chemoRx w or w/o radioRx

Gold standard: ABVD Pt w bulk disease receive radioRx Curative 50-60% Risk of myelosuppression, infertility, 2°

malignancy & organ damage

NON-HODGKIN’S LYMPHOMA (NHL)

Classified separately from HL 70% - 80% are of B Cell origin Incidence 15/100 000 per year in devt

countries Slight ♂ predominance Median age of presentation 55-75y/o Can be classified on the basis of origin

Tumours of B cells Tumours of T cells Tumours of NK cells

AETIOLOGY NHL

Unknown cause; wide geographical variation ?Envt factors

EBV (Burkitt’s lymphoma) ↑% of lymphoma in pts with AIDS H. Pylori in gastric MALT lymphoma

BURKITT LYMPHOMA (AFRICAN SUBTYPE)

PATHOGENESIS NHL

Malignant clonal expansion of lymphocytes Due to errors in gene rearrangements or

recombinations Translocation errors with specific genes

Burkitt’s (c-myc)

CLINICAL FEATURES

Same as HL*

Same as HL

INVESTIGATIONS

CLINICAL DIFFERENCES B/W HL & NHL

Hodgkin’s Lymphoma Non-Hodgkin’s Lymphoma

Often localised to a single axial group of nodes (cervical, mediastinal, para-aortic)

More frequent involvement of multiple peripheral nodes

Orderly spread by contiguity Non-contiguous spread

Mesenteric nodes & Waldeyer ring rarely involved

Mesenteric nodes & Waldeyer ring commonly involved

Extranodal involvement uncommon

Extranodal involvement common

FOLLICULAR B CELL LYMPHOMA

HOPC Asymptomatic w painless generalised lymphadenopathy

Occurs ↓% in Asian population & predominantly in older people (>20-30y/o)

Ix indicates multiple site involvement (Bone marrow infiltration is common)

Runs a remitting & recurring clinical course Death due to:

Rx resistant disease Transformation to Diffuse Large B Cell Lymphoma

Bad prognostic factor, less curable Effects of Rx

MANAGEMENT

Treat the symptoms, not the numbers Leave the asymptomatic pt alone Watchful waiting & repeat biopsies

ChemoRx + RadioRx rCHOP

r = Rituximab C = Cyclophosphamide H = Hydroxydaunorubicin (Doxorubicin) O = Oncovin (Vincristine) P = Prednisolone

WHAT IS RITUXIMAB?

Trade name: Rituxan or Mabthera Chimeric monoclonal antibody against CD20,

found primarily on the surface of B cells CD20 widely expressed on B cells, but is

absent on terminally differentiated plasma cells

Basically, it induces apoptosis of CD20+ cells

DIFFUSE LARGE B CELL LYMPHOMA

Commonest NHL (50% adults) & invariably fatal w/o Rx

Treat to cure, expectant management inappropriate >50% of young pts are cured Contra: Co-morbidities & pt’s will

HOPC Rapidly progressive lymphadenopathy,

symptomatic Infiltration of extranodal organs

Morphology Nuclei of neoplastic B cells are huge (x3-4 of

resting lymphocytes)

DIFFUSE LARGE B CELL LYMPHOMA

MANAGEMENT

Rx decision based on staging Cyclical chemoRx + radioRx

rCHOP Bad prognostic factors

Disease progression during Rx Failure to achieve complete remission during

initial Rx

BURKITT’S LYMPHOMA

Uncommon in the Western world Endemic to Africa

Close assoc w EBV Rapidly fatal w/o Rx HOPC lymphadenopathy, abdo mass, BM &

CNS infiltration (leukaemia & meningitis) Morphology

Starry sky pattern Assoc w translocations involving MYC gene

BURKITT’S LYMPHOMA

MANAGEMENT

Supportive Rx Hydration Prevent Tumour Lysis Syndrome!

Cyclical chemoRx + radioRx rEPOCH

r = Rituximab E = Etoposide P = Prednisolone O = Oncovin (Vincristine) C = Cyclophosphamide H = Hydroxydaunorubicin (Doxorubicin)

?African setting

PERIPHERAL T CELL LYMPHOMA (UNSPECIFIED)

Most common type of adult T-cell lymphoma Most common subtype of peripheral T Cell

lymphoma Often disseminated & aggressive

MANAGEMENT

Treated similarly to B Cell lymphomas Cyclical chemoRx + RadioRx Refer to haematologist

In general, overall Rx strategies are similar but success of complete remission is ↓ than B Cell lymphomas

TUMOUR LYSIS SYNDROME

Iatrogenic cause, Rx causes massive breakdown of tumour cells

Intracellular contents released into circulation Metabolic derangement

Uric acid, potassium & phosphate

Complications Can precipitate Acute Renal Failure

Mgmt Identify high-risk pts Allopurinol given prophylactically Close monitor of electrolytes Baseline ECGs & follow-ups

CASE STUDY #1

62 y/o woman referred for Ix of neck mass HOPC

Enlarging L neck lump over last 6/52, no pain Fatigue, unwell & LOW 3kg

O/E Afebrile, no pallor/jaundice & peripheral oedema BP 170/105 & prominent but undisplaced apex beat L supraclavicular LN (firm, non-tender) Abdo NAD, soft, tender X2 enlarged LN in L groin Urinalysis +1 protein

Other Info Hx of HTN (felodipine 5mg bd) Non-smoker & social drinker

QUESTION TIME

What further info should be elicited from Hx/Ex?

DDx? Ix? Staging the pt? Mgmt & considerations?

INTERESTING FACT OF THE DAY: BREAST IMPLANTATION & LYMPHOMA

Epidemiological studies indicate link b/w silicone breast implants & anaplastic large cell lymphoma (ALCL) ALCL devt in at least 60 women

2/3 occurred in silicone implants 1/3 occurred in saline implants

Considered to be related because ALCL occurred uniformly in breast tissue

FDA labelled silicone as inert, Grade 2 Later relabelled to Grade 3 (somewhat

dangerous)